Grace Therapeutics Inc

Grace Therapeutics Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada The companys lead product candidate is the GTX104 an intravenous infusion to treat subarachnoid hemorrhage It also develops GTX102 an oral mucosal betamethasone spray for the treatment of ataxiatelangiectasia and GTX101 a topical bioadhesive filmforming bupivacaine spray for postherpetic neuralgia The company was formerly known as Acasti Pharma Inc and changed its name to Grace Therapeutics Inc in October 2024 The company was incorporated in 2002 and is headquartered in Princeton New Jersey